Pyxis Oncology, Inc.
Boston, Massachusetts, United States · Biotechnology, Healthcare
Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 44
- Industries
- Biotechnology, Healthcare
- Status
- Public (PYXS)
- Website
- pyxisoncology.com
- Company page
Recent activity at Pyxis Oncology, Inc.
- : SEC 8-K (1.01): On September 29, 2026, Pyxis Oncology, Inc. entered into an Underwriting Agreement with Leerink Partners LLC, Guggenheim Securities, LLC, and Wells Fargo Securities, LLC for an underwritten public offering. The offering includes 36,047,919 shares of common stock and pre-funded warrants to purchase an aggregate of 1,883,121 shares, alongside common warrants to purchase up to 49,310,352 shares. The transaction closed on October 1, 2026, indicating a significant capital raising strategy for the company, and includes terms that allow flexible share issuance to certain investors. This agreement is pivotal for the company's funding and growth initiatives.
- : Pyxis Oncology Secures Funding Through Public Offering
- : SEC 8-K (7.01): On September 9, 2026, Pyxis Oncology, Inc. released a corporate update regarding its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) for patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. This update includes new data from the trial, which aims to evaluate the efficacy and safety of the treatment. The press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2) detail the study's findings and implications for future treatment options in this patient population. The announcement falls under Regulation FD disclosure requirements and was made to keep investors informed about significant developments at the company.
- : Pyxis Oncology Appoints Thomas Civik as Chief Executive Officer
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On June 30, 2026, Pyxis Oncology, Inc. executed a Securities Purchase Agreement for a private placement with institutional and accredited investors, agreeing to issue 19,600,153 shares of common stock at $2.551 per share and common warrants to purchase an equal number of shares at an exercise price of $3.289. The transaction, facilitated by Wells Fargo Securities, LLC, is expected to generate approximately $50.0 million in gross proceeds, anticipated to close on July 2, 2026. These proceeds will support the advancement of Pyxis's lead clinical program, extending its cash runway into the second quarter of 2027. Additionally, a Registration Rights Agreement was entered into on July 2, 2026, to register the resale of these securities by October 2, 2026.
- : Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
- : SEC 8-K (2.02): On March 23, 2026, Pyxis Oncology, Inc. announced its financial results for the full year ended December 31, 2025, revealing critical insights into its performance and future outlook. This report includes detailed financial metrics that denote significant changes compared to previous periods. Additionally, the company provided a corporate update outlining its strategic initiatives and upcoming projects, which may influence investor perception and market positioning. This announcement is crucial for stakeholders evaluating the company's financial health and operational direction.
- : SEC 8-K (7.01): On March 23, 2026, Pyxis Oncology, Inc. made an updated corporate presentation available on its website as part of a Regulation FD Disclosure. This corporate presentation included important information about the company's current position and strategic directions. The update is documented in Exhibit 99.2 of the filing, which also includes a press release dated the same day. This communication aims to ensure transparency with investors and the market, reinforcing the company's commitment to disclosure. The content is not considered filed under the Securities Exchange Act liabilities, highlighting its informative purpose rather than a formal filing.
- : SEC 8-K (8.01):
Pyxis Oncology, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Post-IPO Equity | $150.0M |
| Mar 2021 | Venture | $172.5M |
| Jul 2019 | Venture | $22.0M |
Leadership
- John Flavin, Director
- Geeta Vemuri, Director
- Lucio Iannone, Director
- Jak Knowles, Director
- Christoph Westphal, Director
- David Steinberg, Executive Officer, Director
- Thomas Civik, Chief Executive Officer
- Nelson Azoulay, Chief Business Officer
- Ken Kobayashi, Chief Medical Officer
Verified email and direct lines for Pyxis Oncology, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Pyxis Oncology, Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Pyxis Oncology, Inc. in the news
- Pyxis Oncology to Host Webcast to Present Updated Data from - GlobeNewswire (Sep 08, 2026)
- Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - Morningstar (Sep 09, 2026)
- Pyxis Oncology Announces Proposed Public Offering - GlobeNewswire (Sep 29, 2026)
- Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire (Sep 01, 2026)
- Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board - GlobeNewswire (Sep 08, 2026)
- Pyxis Oncology Announces Up to $114 Million Private - GlobeNewswire (Jun 30, 2026)
Companies similar to Pyxis Oncology, Inc.
- Curevo · Biotechnology, Healthcare
- IntelGenx Technologies Corp. · Biotechnology, Healthcare
- Araceli Biosciences · Biotechnology, Healthcare
- CEL-SCI Corporation · Biotechnology, Healthcare
- Vektor Medical · Biotechnology, Healthcare
About Pyxis Oncology, Inc.: questions and answers
What does Pyxis Oncology, Inc. do?
Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.
Where is Pyxis Oncology, Inc. headquartered?
Pyxis Oncology, Inc. is headquartered in Boston, Massachusetts, United States.
How many employees does Pyxis Oncology, Inc. have?
Pyxis Oncology, Inc. has about 44 employees.
Has Pyxis Oncology, Inc. raised funding?
Yes. Fundz has recorded 3 funding events for Pyxis Oncology, Inc.. The most recent, Post-IPO Equity of $150.0M, was in Sep 2026.
Who leads Pyxis Oncology, Inc.?
Thomas Civik is a Chief Executive Officer at Pyxis Oncology, Inc..
What is the latest news on Pyxis Oncology, Inc.?
On Sep 29, 2026, SEC 8-K (1.01): On September 29, 2026, Pyxis Oncology, Inc. entered into an Underwriting Agreement with Leerink Partners LLC, Guggenheim Securities, LLC, and Wells Fargo Securities, LLC for an underwritten public offering. The offering includes 36,047,919 shares of common stock and pre-funded warran
Is Pyxis Oncology, Inc. a public company?
Yes. Pyxis Oncology, Inc. is publicly traded under the ticker PYXS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy